Diamond Hill Capital Management Inc. bought a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 26,634 shares of the medical instruments supplier's stock, valued at approximately $3,512,000. Diamond Hill Capital Management Inc. owned approximately 0.49% of Mesa Laboratories at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Mesa Laboratories by 20.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier's stock worth $1,312,000 after purchasing an additional 1,708 shares in the last quarter. Barclays PLC boosted its stake in shares of Mesa Laboratories by 357.4% during the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after buying an additional 6,905 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Mesa Laboratories by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 124,761 shares of the medical instruments supplier's stock worth $16,205,000 after buying an additional 5,771 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Mesa Laboratories by 90.3% during the 3rd quarter. Victory Capital Management Inc. now owns 14,001 shares of the medical instruments supplier's stock worth $1,818,000 after buying an additional 6,643 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Mesa Laboratories by 27.8% during the 3rd quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier's stock worth $828,000 after buying an additional 1,403 shares during the last quarter. Institutional investors own 90.60% of the company's stock.
Mesa Laboratories Stock Down 1.5 %
Shares of Mesa Laboratories stock traded down $1.88 during trading hours on Wednesday, reaching $124.24. 66,140 shares of the company's stock were exchanged, compared to its average volume of 36,808. The company has a 50 day moving average of $138.81 and a two-hundred day moving average of $129.23. Mesa Laboratories, Inc. has a fifty-two week low of $83.68 and a fifty-two week high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The stock has a market cap of $675.12 million, a P/E ratio of -2.69 and a beta of 0.82.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, sell-side analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.
Mesa Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, February 28th were paid a dividend of $0.16 per share. The ex-dividend date was Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.52%. Mesa Laboratories's dividend payout ratio is -1.38%.
Mesa Laboratories Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Read More
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
